The president of the European Commission, Ursula von der Leyen, and the president of the United States, Donald Trump, They have reached an agreement to resolve their commercial dispute On the increase in tariffs, community sources have reported. The pact to which the rates have been fixed at 15% to all European imports.
With this agreement reached in Turnberry (Scotland) The threat of Trump is ended, Who warned that if he did not reach an agreement before August 1, the tariffs would be 30%. This has been confirmed by Trump to the media present, in the same way that the EU will make investments in several sectors of the United States worth 660,000 million dollars.
Meanwhile, von der Leyen explained that the agreement includes A fixed and maximum of 15% for “the vast majority of European exports”. “That 15 % will apply” to most sectors, such as cars, semiconductors and pharmaceutical products, “said the president of the EC.
“Zero tariffs” for a series of “strategic products”
He has also indicated that they have agreed “Zero tariffs” for a series of “strategic products” such as aerospace and its components, as well as certain chemical, agricultural products, natural resources or raw materials.
At the same time, Von der Leyen has assured that this agreement will contribute “certainty and stability” for companies and thanked Trump for his “commitment and leadership” to close this pact and has said of him that, “although he is a hard negotiator,” “also forges agreements.”
The pact includes an EU commitment to buy US energy. worth $ 750 billion and invest 600 billion additional dollars In that country, in addition to increasing its acquisitions of US military equipment, Trump previously explained.
Before the meeting they had reported that tariffs were not going to be less than 15%
In his meeting prior to the meeting, the US president already anticipated that he did not contemplate, even in the case of reaching an agreement, that the commercial tariffs of the European Union They were going to be less than 15%something that the Brussels authorities already had.
The US president had also advanced that pharmaceutical products would not be part of a commercial framework because “we have to manufacture them in the United States.”
